Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Abiraterone + Prednisone + Veliparib||Phase II||Actionable||In a Phase II (NCI 9012) trial, addition of Veliparib (ABT-888) to Zytiga (abiraterone) and Prednisone did not improve PSA response rate (72.4% vs 63.9%, p=0.27), measurable disease response rate (52.2% vs 45.0%, p=0.51), or median progression-free survival (10.1 vs 11.0 months, p=0.99) in patients with metastatic castration-resistant prostate cancer (PMID: 29261439; NCT01576172).||29261439|